Medtronic cancels $738 million acquisition of diabetes tech company EOFlow

Medtronic is no longer buying EOFlow, a Korean maker of wearable insulin pumps. The news comes three months after Insulet, EOFlow’s rival, filed a lawsuit accusing the company of stealing trade secrets.

In a filing with the Securities and Exchange Commission late Wednesday, Medtronic announced its cancellation of the deal. The filing is vague, citing “multiple breaches under the agreements” that allow Medtronic to renege. The device giant first announced the acquisition in May for $738 million, giving the company its first tubeless pump.

“We continue to advance our organic efforts and we remain committed to bringing a patch pump to market that integrates our most advanced CGM platform and clinically proven Meal Detection Technology™ algorithm,” Janet Cho, a Medtronic spokesperson, wrote to STAT.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

Log In